Metabolic-disease focused Vogenx priced an $81.3 million IPO to continue development of mizagliflozin, a gut-restricted SGLT1 inhibitor. The lead program is in development for post-bariatric hypoglycemia, gastroparesis, and GIP-dependent Cushing’s syndrome. The financing provides capital to move the candidate across multiple metabolic indications and supports the company’s broader pipeline execution. For investors, the IPO reflects continued appetite for mechanism-led metabolic therapies, particularly those targeting gastrointestinal glucose handling. The company’s stated use of proceeds centers on advancing mizagliflozin through ongoing development milestones across its prioritized set of disorders.